Shield Therapeutics appoints Joanne Estell as CFO

AIM-listed pharmaceutical Shield Therapeutics has poached Stadium Group’s chief financial officer.

Joanne Estell will be the company’s new CFO and a member of the board from 1 May, joining from AIM-quoted technology manufacturer Stadium Group, where she was CFO and company secretary.

Prior to Stadium Group, she was head of mergers and acquisitions at manufacturer Survitec Group, and has worked at costa coffee owner Whitbread and FTSE 100 technology firm Smiths Group.

Founder and chief executive Carl Sterritt said: "Having evaluated, developed and delivered corporate growth strategies, the board and I are particularly looking forward to working closely with Joanne as she plays a pivotal role in Shield's ongoing journey towards becoming a fully-fledged, international and commercially-focused specialty pharmaceutical business."

Estell added: "Shield is delivering growing revenues and expanding its reach within existing markets as well as planning for further international expansion. By working closely with Carl and Shield's highly experienced and driven wider team, my focus will be on effectively supporting our ambitious growth plans so we can deliver increasing value to our shareholders."